Biocon share analysis
Biocon passes 3 of 5 fundamental tests, a score of 6/10. On the daily chart it is in an downtrend, RSI 28, 22% below its 52-week high: downtrend: no long setup. Its own volatility puts the likely range at ₹324.70–₹375.55 a month from now and ₹271.42–₹449.27 in a year (68% bands).
Fundamentals 6/10
- Market cap
- ₹57,190 Cr
- P/E · forward
- 103.3 · 31.9
- PEG · P/B
- — · 1.7
- ROE · net margin
- — · +3%
- Revenue · earnings growth
- +10% · +235%
- Debt / equity
- 42%
- Dividend · beta
- 0.1% · 0.3
- Next results
- 11 Nov 2026
- ✕ Net margin above 10%
- ✕ Revenue growing over 10%
- ✓ Earnings growing
- ✓ Debt/equity under 100%
- ✓ Forward P/E under trailing (earnings expected up)
Swing technicals (daily)
- Trend
- down · 50d below 200d
- RSI(14)
- 28
- 20 / 50 / 200-day avg
- ₹368.73 / ₹392.17 / ₹393.13
- 20-day breakout
- above ₹397.20 · below ₹342.15
- ATR(14)
- ₹8.31 (2.4% a day)
- 52-week range
- ₹337.70 – ₹447.15
- Return 3m · 6m · 1y
- -20% · -0% · -0%
What the price could do
| In | Likely range (68%) |
|---|---|
| 1 mo | ₹324.70 – ₹375.55 (-7% / +8%) |
| 3 mo | ₹307.86 – ₹396.09 (-12% / +13%) |
| 6 mo | ₹292.21 – ₹417.31 (-16% / +20%) |
| 1 year | ₹271.42 – ₹449.27 (-22% / +29%) |
Analysts (19): buy, mean target ₹440.68 (+26%)
From its own volatility (25% a year), no drift assumed: what its swings allow, not a forecast.
Biocon news · last two days
News lean: Neutral- 27h agoBiocon Q2 resultsThe Economic Times
- 4d agoBiocon Chair: AI in Clinical Trials Is the Holy GrailMarketScreener
- 5d agoBiocon clears patent hurdle for breast cancer biosimilar PebrilzoBusiness Standard
- 5d agoBiocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launchThe Economic Times
- 5d agoBiocon secures global settlement with Genentech for Pebrilzo launchExpress Pharma
- 5d agoBiocon settles licence agreement with Genetech for cancer treatment drug — Check earliest secured launch datesCNBCTV18
- 6d agoBiocon founder Kiran Mazumdar Shaw says India must shift pharma industry from generics to innovation-led growthmanufacturing.economictimes.indiatimes
Its order flow and footprint, the AI read of every headline, the expected move, and your own holdings beside it, with your broker connected.
Information and analytics for education only, not investment advice or a recommendation to buy or sell. Alephix Intelligence is not registered with SEBI as an investment adviser or research analyst. Prices may be delayed; figures come from public market data.